Stock Ratings / Health Care / NUVB / forecast

ANIP (70) CMPS (37) RARE (26) STOK (59) ⌘ Pro Terminal →

Nuvation Bio Inc. (Class A) (NUVB) 12-Month Stock Forecast & Price Target Cone

$4.77 +3.92% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)

Nuvation Bio Inc. (Class A) (NUVB) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $1.67B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-13% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NUVB)Realized 20D OHLCV Swing Band: ±10.8%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your NUVB Position Size: $10,000

Shares at $4.77: 2096.4 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $3.24

$6,792

$-3,208 (-32.1%)

12M Consensus BaseTarget $4.15

$8,700

$-1,300 (-13.0%)

12M Bull Case BreakoutTarget $10.24

$21,468

+$11,468 (+114.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$4	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$10	69%	B
JP MorganUS Large-Cap Research	SELL	$4	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NUVB)

✓Walkthrough of NUVB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NUVB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +7.19%📐 HORIZONTAL RANGE

2026-10-30O $4.75H $4.80L $4.60C $4.77VOL 5.06M

RES: $8.86SUP: $4.22SMA50: $5.63SMA200: $5.40

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NUVB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NUVB Butterfly Map → + Track NUVB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NUVB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NUVB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NUVB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NUVB)

Health Care Rank #951 of 1016 ⚔️ ANIP vs NUVB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NUVB vs. ANIP, CMPS, RARE, STOK)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Nuvation Bio Inc. (Class A) (NUVB) ranks #951 by composite RQD confidence (29/100, grade E) and #290 by equity capitalization ($1.67B). Within this direct 5-issuer industry benchmark cohort, ANIP leads on earnings valuation at 21.5x trailing P/E, while ANIP leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. ANIP currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with NUVB at 29/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NUVB ACTIVE Nuvation Bio Inc. (Class A)	E	29/100	—	—	-35.0%	+3.92%	$1.67B	Benchmark Subject
ANIP ANI Pharmaceuticals Inc.	B-	70/100	21.5x	—	16.0%	+2.02%	$1.68B	/anip-vs-nuvb →
CMPS COMPASS Pathways Plc American Depository Shares	D-	37/100	—	—	-35.0%	-0.73%	$1.69B	/cmps-vs-nuvb →
RARE Ultragenyx Pharmaceutical Inc.	E	26/100	—	—	-35.0%	-2.44%	$1.65B	/rare-vs-nuvb →
STOK Stoke Therapeutics Inc.	C-	59/100	—	—	-6.1%	-0.23%	$1.70B	/stok-vs-nuvb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001811063

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nuvation Bio Inc. (Class A) (NUVB) reported GAAP revenue of $62.9M (+699.0% vs. FY2024 revenue of $7.9M ) , GAAP net income of -$204.6M, operating cash flow of -$173.4M, and free cash flow of -$173.4M (-33.0% YoY). On the balance sheet, NUVB closed FY2025 with $594.8M in total assets against $0 in total debt (Altman Z-Score: 0.76, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$62.9M	-$204.6M	-$173.4M	-$173.4M	$594.8M	—
FY2024 (FY)	2024-12-31	$7.9M	-$567.9M	-$130.4M	-$130.4M	$540.6M	—
FY2023 (FY)	2023-12-31	$0	-$75.8M	-$68.0M	-$68.0M	—	—

3. NUVB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NUVB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Nuvation Bio Inc. (Class A) (NYSE: NUVB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $4.77 (+3.92% 1D, market cap $1.67B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NUVB ranks #951 in composite RQD confidence.

How does NUVB compare to ANIP and CMPS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NUVB carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ANIP (ANI Pharmaceuticals Inc.) holds a B- grade (70/100 RQD, P/E 21.5x, ROIC 16.0%, cap $1.68B) and CMPS (COMPASS Pathways Plc American Depository Shares) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.69B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NUVB?

Per NUVB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001811063), Nuvation Bio Inc. (Class A) generated $62.9M in revenue (+699.0% YoY), -$204.6M in net income, and -$173.4M in free cash flow against $594.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NUVB trading relative to its 50-day, 200-day, and 52-week technical levels?

NUVB last traded at $4.77 (+3.92% on volume of 6,497,097 shares), positioning the stock -15.28% below its 50-day simple moving average ($5.63) and -11.67% below its 200-day simple moving average ($5.40). Across its 52-week range of $3.92 to $9.75, NUVB sits at the 14.6% percentile with a 14-day RSI of 42.2 (NEUTRAL RANGE) and an implied next-earnings move of ±10.8% ($4.25 to $5.29).

NUVB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is NUVB's 12-month stock price target?

Nuvation Bio Inc. (Class A) (NUVB) carries a 12-month consensus base price target of $4.15 (-13% from $4.77), with a bull-case target of $10.24 and a bear-case floor of $3.24.

Is NUVB stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates NUVB E (Strong Sell — SELL) with an RQD Confidence score of 29/100.

Direct Sub-Reports: NUVB RQD Cockpit NUVB 12M Forecast NUVB Earnings & Move NUVB Dividends & DRIP NUVB Insiders & 13F NUVB Whale Options NUVB Profit Sankey NUVB News & Why